The One Million Solutions in Health™ Technology Evaluation Consortium™ designated the HemoShear Liver Model as Novel technology via the Signature Square™ program. This technology is one offering from the HemoShear cell-based surrogate system for discovery and assessment of new drug compounds. The Signature Square program provides feedback to technology or service providers (commercial, academic, government, healthcare institutions, etc.) based on confidential reviews by Subject Matter Experts in the life sciences and health care sectors for new or established solutions.
The consortium members independently chose to review this technology and evaluate its role and usefulness in drug safety. Based on their analysis and ratings, the consortium members provided a designation for this solution: HemoShear Liver Model as Novel.
The HemoShear Liver Model is a cell-based surrogate system for discovery and assessment of new drug compounds. The technology has the ability to create physiologically accurate liver conditions that differentiate drug candidates and predict human response at in vivo level drug doses. HemoShear uses actual hemodynamic shear forces experienced by cells in vivo. The hemodynamic patterns are derived from human non-invasive imaging modalities and the HemoShear system accurately recapitulates the regional frequency and “harmony” that cells experience in vivo. When primary cells are placed in this environment, they quickly recalibrate to their in vivo behavior and phenotype. In other systems, static cell cultures, and cell cultures with a simple flow of medium across cells, cannot accurately replicate biology.
“The HemoShear Liver Model technology scored high in Value Proposition,” explained Dawn Van Dam, President and CEO of One Million Solutions in Health. “By engaging the Subject Matter Experts who are interested in drug safety, this platform can continue to contribute by creating tissue models that replicate human diseases and allow for the testing of drug candidates at human concentrations.”
All technologies rated through the Signature Square process are given a designation in one of the four potential technology or service categories: Blockbuster, Novel, Upstart or Innovator. The rating for this patented HemoShear Liver Model as Novel was provided via the evaluation by Subject Matter Experts from around the world. The Signature Square evaluation occurs on two dimensions: 1) Value Proposition to the Marketplace and 2) Market or Partner Readiness.
A One Million Solutions in Health Signature Square evaluation uses a combination of quantitative research, numerical scoring and respondents’ comments, or qualitative feedback, as it reflects the offering’s differentiated position in the market. By focusing on end-user feedback, and applying a graphical treatment and a uniform set of evaluation criteria, a Signature Square helps research teams quickly ascertain how well a technology or service is positioned to provide value to the market and how ready it is to provide that value.
The Signature Square is an opportunity for technology or service providers to receive direct evaluations and feedback which can then be used to inform potential investors, end users and/or partners. It can also be utilized as a component towards understanding the technology or service and its potential to contribute to health care.
The Subject Matter Experts are members of the Technology Evaluation Consortium with specific expertise in the relevant area for each technology, including individuals from top biopharmaceutical, diagnostic, device, health data or healthcare organizations in the field, as relevant. One Million Solutions in Health aims to have a broad representation of feedback and advice from relevant Subject Matter Experts in each area. These experts evaluate the technology or service such that the feedback received is valid and valuable.
The positioning within the Signature Square is related to the aforementioned criteria, along with the point-in-time at which it has been evaluated. Consequently, a technology evaluated early could be considered an Innovator, but by addressing the feedback received in the process, could eventually be considered a Blockbuster.
For an opportunity to join the Technology Evaluation Consortium, and review the detailed information, video and evaluation for this technology: HemoShear Liver Model as Novel, please contact Dawn Van Dam at One Million Solutions in Health (dawn.vandam(at)onemillionsolutionsinhealth.org).
ABOUT ONE MILLION SOLUTIONS IN HEALTH
The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery … of innovative cures, treatments and preventative measures for patients around the world.
In this next year, we will be reviewing 1000’s of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.
We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research and share patient and consumer-focused ideas and solutions.
As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!
ABOUT THE TECHNOLOGY EVALUATION CONSORTIUM
The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.
The model empowers technology providers/scientists and industry end-users to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry and to be the place for the industry to conduct their evaluations and validations.
HemoShear Therapeutics was founded by Drs. Brett Blackman and Brian Wamhoff as a University of Virginia spin-out in 2008. The foundational science was focused on a deep understanding of human disease biology, a philosophy which continues to drive the company goal of accelerating drug discovery and development in the areas of NASH and metabolic rare diseases of the liver.
Since the company’s inception, exceptional scientific and experienced advisory minds have been brought together to develop a novel approach to elucidate the true underlying biology of disease and identify the right targets, which allows for the creation of superior therapeutics for patients who lack safe and effective treatments.